| Type size: |
 |
 |
|
|
Investor Relations
 About Monogram Biosciences, Inc.
Monogram (formerly ViroLogic) advances individualized medicine by developing and marketing innovative products to help guide and improve the treatment of infectious diseases and cancer. Our products are designed to help healthcare providers and pharmaceutical companies select and monitor patients to optimize treatment regimens and develop new and improved antiviral and targeted cancer therapeutics.
Recent Press Releases
Monogram Announces 2008 First Quarter Financial Results
May 01, 2008
HER1 and HER3 VeraTag™ Assays are Now Available for Use in Development and Clinical Evaluation of Cancer Therapeutics
May 01, 2008
Monogram Biosciences Announces First Quarter 2008 Financial Results Conference Call
Apr 21, 2008
Monogram Biosciences to Present at the JMP Securities Seventh Annual Research Conference
Apr 14, 2008
TV Coverage
Toronto: KGO Reports on Prevention and Technology at the International AIDS Conference
Aug. 15, 2006 – ABC affiliate KGO-TV’s Lyanne Melendez reported today on the International AIDS Conference in Toronto where the focus was on prevention tools and the new technology being used to care for HIV/AIDS-infected patients. Monogram's technology and its Trofile co-receptor tropism assay were highlighted.
Stanford: KTVU’s John Fowler Reports on Breakthrough Development of Personalized Medicines
Fox affiliate KTVU-TV in San Francisco aired a story on Monogram Bioscience’s HIV co-receptor tropism assay. In the piece, science reporter John Fowler interviewed a patient and physician using the test at Stanford, and Tien Bui and Bill Young of Monogram. Fowler said the test “removes guesswork from treating difficult disease” and said that “Instead of guessing at what happens…this test actually maps the genetic code of the individual organisms that make each patient sick.”
In his on-set wrap-up of the story, Fowler said that insurance carriers would likely cover it because of the savings incurred by avoiding expensive drug treatments that don’t work.
Webcasts
JMP Securities 7th Annual Research Conference
May 21, 2008
Monogram Biosciences First Quarter 2008 Earnings Conference Call
May 01, 2008
To Investors and Media:
The investor/media pages that follow are your resource for news and financial information about Monogram. In this section you will find information about our current and historical share price, SEC filings, corporate governance, an electronic version of our annual report and frequently asked questions as well as forms to request additional information. The newsroom link provides our most recent and archived press releases, electronic versions of our Corporate Fact Sheet and Backgrounders and links to scientific publications, posters and articles.
Recent Financial Results
Monogram Announces 2007 Year-End Financial Results
Feb 07, 2008
Forward Looking Statements
This website contains forward-looking statements based on certain assumptions and expectations. For this purpose, any statements contained in this website that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "will," "intends" and similar expressions are intended to identify forward-looking statements. These forward-looking statements include references to the potential for an HIV drug that requires a molecular diagnostic for patient selection, FDA approval of maraviroc, plans for further development of the eTag technology and anticipated clinical validation and laboratory validation in a CLIA setting, expected protection provided by recently allowed patents, our ability to advance its opportunities in HIV and oncology, activities expected to occur in connection with the Pfizer collaboration, and the statements under "Outlook." These forward-looking statements are subject to risks and uncertainties and other factors, which may cause actual results to differ materially from the anticipated results or other expectations expressed in such forward-looking statements. These risks and uncertainties include, but are not limited to: the risk that maraviroc will not be approved by the FDA; the risk that regulatory authorities may not require or recommend a molecular diagnostic for patient selection for maraviroc or other HIV drug, risks related to the implementation of the collaboration with Pfizer; risks related to our ability to recognize revenue from activities under the collaboration with Pfizer; risks and uncertainties relating to the performance of our products; the growth in revenues; the size, timing and success or failure of any clinical trials for CCR5 inhibitors, entry inhibitors or integrase inhibitors; the use of our Trofile Assay for patient use in the event of approval of any CCR5 inhibitors; the ability of our eTag assays to predict response to particular therapeutic agents, our ability to obtain additional cohorts of patient samples for additional studies, our ability to successfully conduct clinical studies and the results obtained from those studies; whether larger confirmatory clinical studies will confirm the results of initial studies; our ability to establish reliable, high-volume operations at commercially reasonable costs; expected reliance on a few customers for the majority of our revenues; the annual renewal of certain customer agreements; actual market acceptance of our products and adoption of our technological approach and products by pharmaceutical and biotechnology companies; our estimate of the size of our markets; our estimates of the levels of demand for our products; the impact of competition; the timing and ultimate size of pharmaceutical company clinical trials; seasonal effects on revenue due to holiday periods which often affect the first and third quarters; whether payers will authorize reimbursement for our products and services; whether the FDA or any other agency will decide to further regulate our products or services, whether the draft guidance on Multivariate Index Assays recently issued by FDA applies to our current or planned products; whether we will encounter problems or delays in automating our processes; the ultimate validity and enforceability of our patent applications and patents; the possible infringement of the intellectual property of others; whether licenses to third party technology will be available; whether we are able to build brand loyalty and expand revenues; restrictions on the conduct of our business imposed by the Pfizer and Merrill Lynch debt agreements; the impact of additional dilution if our convertible debt is converted to equity; and whether we will be able to raise sufficient capital in the future, if required. For a discussion of other factors that may cause actual events to differ from those projected, please refer to our most recent annual report on Form 10-K and quarterly reports on Form 10-Q, as well as other subsequent filings with the Securities and Exchange Commission. We do not undertake, and specifically disclaim any obligation, to revise any forward-looking statements to reflect the occurrence of anticipated or unanticipated events or circumstances after the date of such statements.
|
 |
| NASDAQ |
MGRM |
| Last Sale |
$1.08 |
| Change Net |
+ $0.03 |
| Change % |
+ 2.86% |
| Share Volume |
664,900 |
| As of |
4:11 PM ET 05/09/08 |
 |
|
 |
|
 |
American Stock Transfer & Trust Co.
59 Maiden Lane
New York, NY 10038
Phone 212-936-5100
|
|
 |
|
|
